International trial confirms long-term benefits of anastrozole to stop breast cancer

November 20, 2015

Around 32,000 postmenopausal women are diagnosed with breast cancer every year in the UK3, so the results of this trial could lead to over a thousand fewer women developing a recurrence of their breast cancer each year.

Both anastrozole and tamoxifen work by interfering with the female hormone oestrogen4, which is known to be the most important cause of breast cancer.

Kate Law, Cancer Research UK's director of clinical research, said: "Drugs like tamoxifen and now anastrozole have made a significant contribution to the impressive survival rates we see for breast cancer today by cutting the risk of the disease coming back.

"Anastrozole is one of three aromatase inhibitors currently prescribed to help prevent breast cancer coming back in postmenopausal women - the highest risk group. But all drugs have side-effects and it's essential we continue to monitor the long-term performance of these drugs before we can conclusively say which is the safest and best option for this group of women."

Source: Cancer Research UK